Results 41 to 50 of about 23,497 (215)
Personalizing HIV therapy, mission impossible? [PDF]
, 2012 Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core +1 more source
Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
Biology, 2012 HIV-1 Reverse Transcriptase (RT) is a multifunctional enzyme responsible for the transcription of the RNA genome of the HIV virus into DNA suitable for incorporation within the DNA of human host cells. Its crucial role in the viral life cycle has made it
Peter V. Coveney +3 more
doaj +1 more source
Stem Cell Research & Therapy, 2022 Background To determine the effects of integrase inhibitor (INSTI) in comparison with non-INSTI-based regimens such as non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based regimens on cardiovascular disease (CVD) risk in HIV+ patients without ...
Adrian Farid Elzarki +4 more
doaj +1 more source
Focus on chirality of HIV-1 non-nucleoside reverse transcriptase inhibitors [PDF]
, 2016 Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains.
Famiglini, Valeria, Silvestri, Romano
core +2 more sources
Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018 Introduction: After introduction of highly active anti-retroviral treatment (HAART), the mortality and morbidity rates among HIV/AIDS patients have been reduced. CD4+ T cell and HIV RNA measurement is important in the follow-up during the treatment.
Ufuk SÖNMEZ +4 more
doaj +1 more source
The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]
, 2020 BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott +9 more
core
Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort [PDF]
, 2018 BACKGROUND: Globally, 49% of the estimated 1.8 million children living with HIV are accessing antiretroviral therapy (ART). There are limited data concerning long-term durability of first-line ART regimens and time to transition to second-line ...
Ayaya, Samuel +16 more
core +2 more sources
Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. [PDF]
, 2007 OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions.
Bartlett +35 more
core +2 more sources
Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice – 2-year data from the German Outpatient Cohort [PDF]
, 2008 Poster presentation: Purpose of the study First-line HAART with tenofovir DF (TDF) and FTC in pivotal trials has been associated with high efficacy and good tolerability.
Braun, Patrick +8 more
core +1 more source
AIDS Research and Therapy, 2020 Background Pre-treatment drug resistance (PDR) among antiretroviral drug-naïve people living with HIV (PLHIV) represents an important indicator for the risk of treatment failure and the spread of drug resistant HIV variants. We assessed the prevalence of
F. Neuhann +9 more
doaj +1 more source